Outcome determinants in acute lung injury

**P248** MEASURING PHYSICAL RECOVERY IN THE CRITICAL CARE POPULATION: DEVELOPMENT OF THE CHELSEA CRITICAL CARE PHYSICAL ASSESSMENT TOOL (CPAX)

doi:10.1136/thx.2010.151068.49

1E J Corner, 1H Wood, 1C Englebretsen, 2S Boot, 3D Nikoletou. 1Chelsea and Westminster Hospital NHS Trust, London, UK; 2Barts and The London NHS Trust, London, UK; 3St George’s, University of London, London, UK

**Introduction** The secondary physical effects of critical illness, for example, muscle atrophy, can be detrimental to functional outcome and quality of life in critical care survivors. To minimise these problems early physiotherapy in the Intensive Care Unit (ICU) is advocated. However, research to identify the optimal rehabilitation strategy is hindered by lack of an ICU specific objective measure of physical recovery. Current measures are either impairment specific, thus not capturing the full picture, or their validity is unproven in this population.

**Aim** To develop a measurement tool to assess physical recovery in the heterogeneous general adult critical care population.

**Method**

**Face/content validity** The initial tool was developed in a clinical setting by specialist physiotherapists and is called the Chelsea Critical Care Physical Assessment tool (CPAX). It is a pictorial composite of 10 numerical evaluations of pertinent functions and impairments. It was tested for face and content validity with a content validity index questionnaire (CVIQ), a subsequent focus group and a repeat CVIQ.

**Construct validity** A dual centred cohort study of 32 ICU patients was completed. Treating physiotherapists assessed patients using the CPAX thrice weekly. Additionally, biceps and quadriceps strength, cough peak flow (CPF) and components of the AusTOMs scores (a physiotherapy outcome measure) were tested by a researcher blinded to the CPAX scores. Correlation co-efficients were then used to analyse the data.

**Reliability** Reliability was strong with internal consistency of 0.98 and ICC 0.902 (95% CI 0.799 to 0.969; *p*<0.001).

**Results**

**Face/content validity** Pre and post focus group CVIs were 0.67 (p>0.05) and 0.83 (p<0.05), respectively.

**Construct validity** Pilot data showed strong positive correlations (0.744 to 0.922, *p*<0.01), between the CPAX, muscle strength and AusTOMs scores. Data were insufficient to analyse CPF results.

**Conclusion** Preliminary data show that the CPAX is a reliable and valid measure of physical function in ICU patients. It can now be used as an outcome measure for physiotherapy research and has potential to act as a predictor of functional outcome in the ICU population.

---

**P249** PHYSICIANS’ OPINION: CEILINGS OF THERAPY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PILOT STUDY)

doi:10.1136/thx.2010.151068.50

1J L Gallagher, 2B Morton, 3I Clegg, 2J Walker, 1L Davies. 1Aintree University Hospital Foundation Trust, Liverpool, UK; 2Royal Liverpool University Hospital Trust, Liverpool, UK; 3Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

**Introduction** Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a common reason for hospital admission. Treatment depends upon the severity of presentation and background physiological status. The COPD NICE guidelines (2010) state that when patients are started on NIV, there should be a clear plan covering what to do in the event of deterioration and ceilings of therapy should be agreed.1 We sought to explore decision making among clinicians with responsibility for interventional treatments in difficult scenarios.

**Method**

We questioned intensive care and respiratory clinicians in two deaneries. We described six hypothetical patients with COPD who presented to an A&E department in hypercapnic respiratory failure. The histories given were of end stage COPD, ischaemic heart disease, complicated diabetes mellitus, advanced age, potentially curable bronchial carcinoma and non-concordance with treatment.

**Results**

One hundred and thirteen questionnaires were collected; 58 intensive care medicine (ICM) clinicians (28 consultant and 30 specialist trainees) and 55 respiratory medicine physicians (13 consultant and 42 specialist trainees). The majority of respondents would intervene in the presented scenarios, either with invasive or non-invasive ventilation as illustrated in graph 1. No statistical difference in decision making was demonstrated between ICM and respiratory clinicians. Statistical kappa analysis (Intercooled Stata 9.0) demonstrated fair agreement among ICM trainees, respiratory trainees and consultants when choosing non-invasive (0.32, 0.41, 0.33) and invasive ventilation (0.29, 0.39, 0.36) with ‘slight’ agreement among ICM consultants (non-invasive 0.12 and invasive ventilation 0.22). Some respiratory physicians felt that they required additional information, such as results of spirometry, to make informed decisions. However, in an acute setting, such information is often unavailable so was not included in the vignettes. The opportunistic nature of data collection meant that a response rate could not be calculated.

**Conclusion**

This pilot study did not demonstrate a difference in decision making between respiratory and intensive care specialities. With development of the vignettes this methodology could form the basis for a national survey on ceilings of therapy in COPD to inform the individual clinician when making difficult decisions.

---

Abstract P248 Table 1 Construct validity data

<table>
<thead>
<tr>
<th>AusTOMs BPCA</th>
<th>AusTOMs BPCI</th>
<th>AusTOMs MSKA</th>
<th>AusTOMs MSKI</th>
<th>Left Briceps</th>
<th>Right Briceps</th>
<th>Right Quadriceps</th>
<th>Left Quadriceps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correlation Coefficient with the CPAX score</td>
<td>0.922*</td>
<td>0.892*</td>
<td>0.888*</td>
<td>0.844*</td>
<td>0.756*</td>
<td>0.765*</td>
<td>0.744*</td>
</tr>
<tr>
<td>Number of patient measurements</td>
<td>42</td>
<td>40</td>
<td>42</td>
<td>41</td>
<td>42</td>
<td>42</td>
<td>42</td>
</tr>
</tbody>
</table>

*Correlation is significant to the level p<0.01.

Abstract P249 Figure 1

**Ceilings of Treatment in COPD (n=113)**

- 0.0% - 0.5%
- 0.5% - 1.0%
- 1.0% - 1.5%
- 1.5% - 2.0%
- 2.0% - 2.5%
- 2.5% - 3.0%
- 3.0% - 3.5%
- 3.5% - 4.0%
- 4.0% - 4.5%
- 4.5% - 5.0%
- 5.0% - 5.5%
- 5.5% - 6.0%
- 6.0% - 6.5%
- 6.5% - 7.0%
- 7.0% - 7.5%
- 7.5% - 8.0%